EVOLUS, INC. Accounts Receivable, Allowance for Credit Loss
EVOLUS, INC. (EOLS) had Accounts Receivable, Allowance for Credit Loss of $4.92 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-08-05
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $4.92M.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $4.88M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $5.29M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $4.87M.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $4.92M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $4.88M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $5.29M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $4.87M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $3.53M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $2.88M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.71M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.28M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $2.06M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $1.78M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.49M 10-K · filed 2025-03-04 |
| 2023-09-30 | $2.45M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $2.50M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $2.32M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $2.05M 10-K · filed 2025-03-04 |
| 2022-09-30 | $3.27M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $3.04M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $2.83M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.38M 10-K · filed 2023-03-08 |
| 2021-09-30 | $2.38M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $2.22M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $2.56M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $2.12M 10-K · filed 2022-03-03 |
| 2020-09-30 | $2.66M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $2.82M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.82M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $387.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |